Cargando…
Quality of randomized controlled trials reporting in the treatment of melasma conducted in china
BACKGROUND: There is no existing report on the quality of randomized controlled trials (RCTs) of melasma treatment currently conducted in China. This study aims to assess the quality of RCT- reporting in the treatment of melasma conducted in China. METHODS: Several databases were searched from their...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399216/ https://www.ncbi.nlm.nih.gov/pubmed/25872530 http://dx.doi.org/10.1186/s13063-015-0677-2 |
_version_ | 1782366913602519040 |
---|---|
author | Chen, Zhiwei Chen, Yuchi Zeng, Jingchun Wang, Yang Ye, Teng Zhou, Qiaochu Du, Xiaojing Su, Wenting Ding, Zhishan |
author_facet | Chen, Zhiwei Chen, Yuchi Zeng, Jingchun Wang, Yang Ye, Teng Zhou, Qiaochu Du, Xiaojing Su, Wenting Ding, Zhishan |
author_sort | Chen, Zhiwei |
collection | PubMed |
description | BACKGROUND: There is no existing report on the quality of randomized controlled trials (RCTs) of melasma treatment currently conducted in China. This study aims to assess the quality of RCT- reporting in the treatment of melasma conducted in China. METHODS: Several databases were searched from their inception through to August 2014. In order to rate the report quality, we scored 1 for the item if it was reported in CONSORT 2010 and 0 for the item if it was not definitely stated or was not clear. For overall quality score (OQS), 13 items were scored and calculated with a range of 0 to 13. Five items (‘randomization’, ‘allocation concealment’, ‘blinding’, ‘baseline characteristics’ and ‘intention-to-treat (ITT) analysis’) were scored and a key methodological index score (MIS) was calculated with a range of 0 to 5 for each trial. RESULTS: A total of 246 relevant RCTs were included in the final analysis. The median OQS was 7, with a minimum of 4 and a maximum of 11. Some items’ information was insufficient, especially in the categories of ‘trial design’, ‘sample size’, ‘recruitment’ and ‘ancillary analyses’ with a positive rate of less than 20%. The median MIS was 1 with a minimum of 0 and a maximum of 3. Some items’ reporting was poor, especially in the categories of ‘randomization’, ‘allocation concealment and implementation’, ‘blinding’ and ‘ITT analysis’ with a positive rate of less than 10%. The mean OQS increased by about 0.52 for manuscripts published in the period of 5-year increments (95% CI: 0.32 to 0.72; P < 0.001). With regard to the MIS, no variable was statistically significant in the ordinal regression model. CONCLUSION: The reporting quality of RCTs in the treatment of melasma conducted in China is not satisfactory especially in key methodological items. Reporting of RCTs in this field should meet and keep up with the standards of the CONSORT statement. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-015-0677-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4399216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43992162015-04-17 Quality of randomized controlled trials reporting in the treatment of melasma conducted in china Chen, Zhiwei Chen, Yuchi Zeng, Jingchun Wang, Yang Ye, Teng Zhou, Qiaochu Du, Xiaojing Su, Wenting Ding, Zhishan Trials Research BACKGROUND: There is no existing report on the quality of randomized controlled trials (RCTs) of melasma treatment currently conducted in China. This study aims to assess the quality of RCT- reporting in the treatment of melasma conducted in China. METHODS: Several databases were searched from their inception through to August 2014. In order to rate the report quality, we scored 1 for the item if it was reported in CONSORT 2010 and 0 for the item if it was not definitely stated or was not clear. For overall quality score (OQS), 13 items were scored and calculated with a range of 0 to 13. Five items (‘randomization’, ‘allocation concealment’, ‘blinding’, ‘baseline characteristics’ and ‘intention-to-treat (ITT) analysis’) were scored and a key methodological index score (MIS) was calculated with a range of 0 to 5 for each trial. RESULTS: A total of 246 relevant RCTs were included in the final analysis. The median OQS was 7, with a minimum of 4 and a maximum of 11. Some items’ information was insufficient, especially in the categories of ‘trial design’, ‘sample size’, ‘recruitment’ and ‘ancillary analyses’ with a positive rate of less than 20%. The median MIS was 1 with a minimum of 0 and a maximum of 3. Some items’ reporting was poor, especially in the categories of ‘randomization’, ‘allocation concealment and implementation’, ‘blinding’ and ‘ITT analysis’ with a positive rate of less than 10%. The mean OQS increased by about 0.52 for manuscripts published in the period of 5-year increments (95% CI: 0.32 to 0.72; P < 0.001). With regard to the MIS, no variable was statistically significant in the ordinal regression model. CONCLUSION: The reporting quality of RCTs in the treatment of melasma conducted in China is not satisfactory especially in key methodological items. Reporting of RCTs in this field should meet and keep up with the standards of the CONSORT statement. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-015-0677-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-12 /pmc/articles/PMC4399216/ /pubmed/25872530 http://dx.doi.org/10.1186/s13063-015-0677-2 Text en © Chen et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Chen, Zhiwei Chen, Yuchi Zeng, Jingchun Wang, Yang Ye, Teng Zhou, Qiaochu Du, Xiaojing Su, Wenting Ding, Zhishan Quality of randomized controlled trials reporting in the treatment of melasma conducted in china |
title | Quality of randomized controlled trials reporting in the treatment of melasma conducted in china |
title_full | Quality of randomized controlled trials reporting in the treatment of melasma conducted in china |
title_fullStr | Quality of randomized controlled trials reporting in the treatment of melasma conducted in china |
title_full_unstemmed | Quality of randomized controlled trials reporting in the treatment of melasma conducted in china |
title_short | Quality of randomized controlled trials reporting in the treatment of melasma conducted in china |
title_sort | quality of randomized controlled trials reporting in the treatment of melasma conducted in china |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399216/ https://www.ncbi.nlm.nih.gov/pubmed/25872530 http://dx.doi.org/10.1186/s13063-015-0677-2 |
work_keys_str_mv | AT chenzhiwei qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina AT chenyuchi qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina AT zengjingchun qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina AT wangyang qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina AT yeteng qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina AT zhouqiaochu qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina AT duxiaojing qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina AT suwenting qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina AT dingzhishan qualityofrandomizedcontrolledtrialsreportinginthetreatmentofmelasmaconductedinchina |